A clinical trial for the efficacy and safety of new Chinese herbal compound in reducing uric acid in patients
Phase 1
Not yet recruiting
- Conditions
- Hyperuricemia
- Registration Number
- ITMCTR2000003495
- Lead Sponsor
- Tongren of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Male and female aged 18 to 65 years; patients with a diagnosis of HUA [sUA levels >=420 umol/L (7 mg/dL)in male and 360 umol/L in female]; Patients with gout and high uric acid.
Exclusion Criteria
Patients were excluded with HIV positive, hepatitis B or C infection, pregnant or lactating women, and active infection.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the uric acid-lowering effects of the new Chinese herbal compound in ITMCTR2000003495?
How does the new Chinese herbal compound compare to allopurinol in managing hyperuricemia in phase I trials?
Are there specific biomarkers associated with response to the new Chinese herbal compound for hyperuricemia treatment?
What adverse events are reported in phase I trials of the new Chinese herbal compound for uric acid reduction?
What are the key differences between the new Chinese herbal compound and other uric acid-lowering agents in clinical development?